CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
215.40
0.31%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Thu: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.31
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Biogen Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 216.06
Open* 216.13
1-Year Change* -19.66%
Day's Range* 214.65 - 216.13
52 wk Range 220.86-319.76
Average Volume (10 days) 978.65K
Average Volume (3 months) 22.56M
Market Cap 35.79B
P/E Ratio 24.57
Shares Outstanding 144.90M
Revenue 9.99B
EPS 10.05
Dividend (Yield %) N/A
Beta 0.01
Next Earnings Date Feb 13, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 216.06 3.26 1.53% 212.80 216.21 212.55
Mar 26, 2024 211.37 -4.13 -1.92% 215.50 216.24 210.97
Mar 25, 2024 216.52 -0.95 -0.44% 217.47 218.11 215.49
Mar 22, 2024 217.94 -3.02 -1.37% 220.96 220.96 215.28
Mar 21, 2024 220.70 2.21 1.01% 218.49 221.50 216.95
Mar 20, 2024 217.98 1.50 0.69% 216.48 219.20 215.59
Mar 19, 2024 218.49 0.70 0.32% 217.79 218.91 215.36
Mar 18, 2024 219.19 -0.03 -0.01% 219.22 220.25 217.27
Mar 15, 2024 218.62 -0.44 -0.20% 219.06 220.67 216.60
Mar 14, 2024 219.50 -5.15 -2.29% 224.65 225.59 218.38
Mar 13, 2024 226.49 -0.84 -0.37% 227.33 229.63 224.91
Mar 12, 2024 227.30 -0.17 -0.07% 227.47 229.08 224.98
Mar 11, 2024 229.92 6.97 3.13% 222.95 230.08 222.95
Mar 8, 2024 223.11 -1.91 -0.85% 225.02 227.95 220.74
Mar 7, 2024 219.16 0.21 0.10% 218.95 219.61 215.84
Mar 6, 2024 217.47 0.52 0.24% 216.95 219.83 216.70
Mar 5, 2024 217.05 -1.84 -0.84% 218.89 221.34 216.35
Mar 4, 2024 220.80 0.37 0.17% 220.43 222.78 219.07
Mar 1, 2024 220.03 3.08 1.42% 216.95 221.82 215.14
Feb 29, 2024 216.86 -5.72 -2.57% 222.58 222.58 216.04

Biogen Inc. Events

Time (UTC) Country Event
Tuesday, April 23, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Biogen Inc Earnings Release
Q1 2024 Biogen Inc Earnings Release

Forecast

-

Previous

-
Tuesday, June 25, 2024

Time (UTC)

13:00

Country

US

Event

Biogen Inc Annual Shareholders Meeting
Biogen Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 10173.4 10981.7 13444.6 14377.9 13452.9
Revenue 10173.4 10981.7 13444.6 14377.9 13452.9
Cost of Revenue, Total 2278.3 2109.7 1805.2 1955.4 1816.3
Gross Profit 7895.1 8872 11639.4 12422.5 11636.6
Total Operating Expense 6101.4 8141 8894.5 7335.3 7564.3
Selling/General/Admin. Expenses, Total 2430 2702.4 2535 2357 2106.3
Research & Development 2228.7 2497 3984.6 2272.7 2597.2
Depreciation / Amortization 246.3 252 255.1 274 381.2
Interest Expense (Income) - Net Operating -7.4 7.2 232.9 241.6 185
Unusual Expense (Income) -841.4 647.3 192.2 272.7 490.6
Other Operating Expenses, Total -233.1 -74.6 -110.5 -38.1 -12.3
Operating Income 4072 2840.7 4550.1 7042.6 5888.6
Interest Income (Expense), Net Non-Operating -470.1 -1089.9 494.5 137.3 21.5
Other, Net -10.1 -5.6 2.9 -54 -10.5
Net Income Before Taxes 3591.8 1745.2 5047.5 7125.9 5899.6
Net Income After Taxes 2959 1692.7 4055.2 5967.9 4497.7
Minority Interest 85.3 -171.5 -59.9 0 -43.3
Equity In Affiliates 2.6 34.9 5.3 -79.4 0
Net Income Before Extra. Items 3046.9 1556.1 4000.6 5888.5 4454.4
Net Income 3046.9 1556.1 4000.6 5888.5 4430.7
Income Available to Common Excl. Extra. Items 3046.9 1556.1 4000.6 5888.5 4454.4
Income Available to Common Incl. Extra. Items 3046.9 1556.1 4000.6 5888.5 4430.7
Diluted Net Income 3046.9 1556.1 4000.6 5888.5 4430.7
Diluted Weighted Average Shares 146 149.6 161.3 187.4 205.3
Diluted EPS Excluding Extraordinary Items 20.8692 10.4017 24.8022 31.4221 21.697
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS 16.1215 14.6021 25.851 32.6408 23.6491
Total Extraordinary Items -23.7
Dilution Adjustment 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 2456 2463 2544 2508.5 2589.1
Revenue 2456 2463 2544 2508.5 2589.1
Cost of Revenue, Total 592.7 662.8 570.9 469.5 484
Gross Profit 1863.3 1800.2 1973.1 2039 2105.1
Total Operating Expense 1869.1 1955.3 1844.1 1193.4 1142.8
Selling/General/Admin. Expenses, Total 548 605 632.8 563.3 572.6
Research & Development 584.2 570.6 601.6 549.2 528.6
Depreciation / Amortization 52.9 50.2 55.4 56.5 67.5
Interest Expense (Income) - Net Operating 56.9 57.1 35.2 45.3 29.4
Unusual Expense (Income) 34.4 9.6 143.6 -488.3 -534.8
Other Operating Expenses, Total 0 0 -195.4 -2.1 -4.5
Operating Income 586.9 507.7 699.9 1315.1 1446.3
Interest Income (Expense), Net Non-Operating 123.5 -70 -111.2 54.3 -150.6
Other, Net -2.3 0.6 15.1 1.7 -26.2
Net Income Before Taxes 708.1 438.3 603.8 1371.1 1269.5
Net Income After Taxes 593.3 387.6 549.5 1134.9 1052.8
Minority Interest -1.7 0.3 0.9 -0.2 -0.7
Equity In Affiliates 0 0 0 0 5.9
Net Income Before Extra. Items 591.6 387.9 550.4 1134.7 1058
Net Income 591.6 387.9 550.4 1134.7 1058
Income Available to Common Excl. Extra. Items 591.6 387.9 550.4 1134.7 1058
Income Available to Common Incl. Extra. Items 591.6 387.9 550.4 1134.7 1058
Diluted Net Income 591.6 387.9 550.4 1134.7 1058
Diluted Weighted Average Shares 145.5 145.2 145.4 144.8 146.2
Diluted EPS Excluding Extraordinary Items 4.06598 2.67149 3.78542 7.83633 7.23666
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 4.26408 2.72996 4.68422 5.04503 4.20307
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 9791.2 7856.5 6887.1 8381.8 7640.9
Cash and Short Term Investments 4892.8 3802.5 2610.1 4475.9 3538
Cash & Equivalents 3419.3 2261.4 1331.2 2913.7 1224.6
Short Term Investments 1473.5 1541.1 1278.9 1562.2 2313.4
Total Receivables, Net 2136.4 1961.7 2327.3 2470.7 2485.4
Accounts Receivable - Trade, Net 2136.4 1961.7 2327.3 2470.7 2485.4
Total Inventory 1344.4 1351.5 1068.6 804.2 929.9
Prepaid Expenses
Other Current Assets, Total 1417.6 740.8 881.1 631 687.6
Total Assets 24554.1 23877.3 24618.9 27234.3 25288.9
Property/Plant/Equipment, Total - Net 3702.5 3791.8 3844.8 3674.3 3601.2
Property/Plant/Equipment, Total - Gross 5868.2 5798.4 5627.1 5265.2 5398.6
Accumulated Depreciation, Total -2165.7 -2006.6 -1782.3 -1590.9 -1797.4
Goodwill, Net 5749 5761.1 5762.1 5757.8 5706.4
Intangibles, Net 1850.1 2221.3 3084.3 3527.4 3120
Long Term Investments 2234.9 2831.5 3671.1 2653.9 3038.5
Other Long Term Assets, Total 1226.4 1415.1 1369.5 3239.1 2181.9
Total Current Liabilities 3272.8 4298.2 3742.2 4863.8 3295.2
Accounts Payable 491.5 589.2 454.9 530.8 370.5
Accrued Expenses 1593.8 1471 1716.1 1682.7 1545.5
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 999.1 0 1495.8 0
Other Current Liabilities, Total 1187.5 1238.9 1571.2 1154.5 1379.2
Total Liabilities 11156.2 12981.1 13918.6 13891.1 12249.3
Total Long Term Debt 6281 6274 7426.2 4459 5936.5
Long Term Debt 6281 6274 7426.2 4459 5936.5
Capital Lease Obligations
Deferred Income Tax 334.7 694.5 1032.8 2810.8 1636.2
Minority Interest -9.5 63.5 -14.2 -4.1 -8
Other Liabilities, Total 1277.2 1650.9 1731.6 1761.6 1389.4
Total Equity 13397.9 10896.2 10700.3 13343.2 13039.6
Common Stock 0.1 0.1 0.1 0.1 0.1
Additional Paid-In Capital 73.3 68.2 0 0 0
Retained Earnings (Accumulated Deficit) 16466.5 13911.7 13976.3 16455.4 16257
Treasury Stock - Common -2977.1 -2977.1 -2977.1 -2977.1 -2977.1
Unrealized Gain (Loss) -15.7 -2.2 1.4 4.2 -4
Other Equity, Total -149.2 -104.5 -300.4 -139.4 -236.4
Total Liabilities & Shareholders’ Equity 24554.1 23877.3 24618.9 27234.3 25288.9
Total Common Shares Outstanding 144.1 147 152.4 174.2 197.2
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 8454.1 10431.7 9762.5 9791.2 9765.8
Cash and Short Term Investments 2287.9 6078.3 5041.3 4892.8 4911.1
Cash & Equivalents 2287.9 2617.8 2898.2 3419.3 3675.6
Short Term Investments 0 3460.5 2143.1 1473.5 1235.5
Total Receivables, Net 2209.7 2124 2028.2 2136.4 1984.2
Accounts Receivable - Trade, Net 2209.7 2124 2028.2 2136.4 1984.2
Total Inventory 2982.4 1333.5 1281 1344.4 1375
Other Current Assets, Total 974.1 895.9 1412 1417.6 1495.5
Total Assets 28193.2 25156.8 24598.4 24554.1 24854.2
Property/Plant/Equipment, Total - Net 3762.5 3673.7 3700 3702.5 3690.9
Property/Plant/Equipment, Total - Gross 5644.3 5589.3 5519.1 5464.3 5364.4
Accumulated Depreciation, Total -2342.7 -2282.1 -2218.2 -2165.7 -2098
Goodwill, Net 6807.5 5753.7 5751.8 5749 5741.2
Intangibles, Net 7344.6 1776.4 1813.3 1850.1 2008.9
Long Term Investments 754.7 2312.9 2359 2234.9 2472.9
Other Long Term Assets, Total 1069.8 1208.4 1211.8 1226.4 1174.5
Total Current Liabilities 5022.3 3186.5 3014.9 3272.8 3926.4
Accounts Payable 440.1 445.4 491.2 491.5 383.2
Accrued Expenses 2827.4 1423 1278.3 1593.8 1376.6
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1254.8 1318.1 1245.4 1187.5 2166.6
Total Liabilities 13709.4 10689.9 10801.8 11156.2 12078.7
Total Long Term Debt 6786.4 6284.6 6282.7 6281 6279.2
Long Term Debt 6786.4 6284.6 6282.7 6281 6279.2
Deferred Income Tax 728.1 143.9 251.3 334.7 328.9
Minority Interest -4.1 -6.4 -9.6 -9.5 -8.7
Other Liabilities, Total 1176.7 1081.3 1262.5 1277.2 1552.9
Total Equity 14483.8 14466.9 13796.6 13397.9 12775.5
Common Stock 0.1 0.1 0 0.1 0.1
Additional Paid-In Capital 242.2 170.7 91.2 73.3 0
Retained Earnings (Accumulated Deficit) 17377.9 17446 16854.4 16466.5 15916.1
Treasury Stock - Common -2977.1 -2977.1 -2977.1 -2977.1 -2977.1
Unrealized Gain (Loss) 0 -14.5 -10 -15.7 -21.2
Other Equity, Total -159.3 -158.3 -161.9 -149.2 -142.4
Total Liabilities & Shareholders’ Equity 28193.2 25156.8 24598.4 24554.1 24854.2
Total Common Shares Outstanding 144.9 144.8 144.8 144.1 144
Current Port. of LT Debt/Capital Leases 500 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 2961.6 1727.6 4060.5 5888.5 4474
Cash From Operating Activities 1384.3 3639.9 4229.8 7078.6 6187.7
Cash From Operating Activities 518.4 487.7 457.2 680.6 1016.6
Deferred Taxes -168.6 -426.8 149 67.1 108.3
Non-Cash Items -1036.8 1996.9 -249.7 243.1 188.6
Cash Taxes Paid 932.9 247.9 906.7 1064.5 1007.1
Cash Interest Paid 262.5 280.8 272.7 244.2 243.2
Changes in Working Capital -890.3 -145.5 -187.2 199.3 400.2
Cash From Investing Activities 1576.6 -563.7 -608.6 470.5 -2046.3
Capital Expenditures -243.2 -294.9 -551.8 -669.5 -886.1
Other Investing Cash Flow Items, Total 1819.8 -268.8 -56.8 1140 -1160.2
Cash From Financing Activities -1747.3 -2086.2 -5272.7 -5860.4 -4472
Financing Cash Flow Items 4.9 -116.2 -61 7.9 -116.2
Issuance (Retirement) of Stock, Net -750 -1800 -6679.1 -5868.3 -4352.6
Issuance (Retirement) of Debt, Net -1002.2 -170 1467.4 0 -3.2
Foreign Exchange Effects -55.7 -59.8 69 0.4 -18.6
Net Change in Cash 1157.9 930.2 -1582.5 1689.1 -349.2
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 387.6 2961.6 2412.1 1277.2 218.5
Cash From Operating Activities 455.3 1384.3 1559.3 898.3 161.8
Cash From Operating Activities 112.3 518.4 398.6 277.9 143.1
Deferred Taxes -64.5 -168.6 -139.8 -47.5 1
Non-Cash Items 204 -1036.8 -1208.8 -709.2 579.7
Changes in Working Capital -184.1 -890.3 97.2 99.9 -780.5
Cash From Investing Activities -953 1576.6 1717.7 45.5 -648
Capital Expenditures -71.6 -243.2 -155.8 -96.7 -57.9
Other Investing Cash Flow Items, Total -881.4 1819.8 1873.5 142.2 -590.1
Cash From Financing Activities -43.4 -1747.3 -1739.9 -488 -16.5
Financing Cash Flow Items -43.4 4.9 12.3 12 -16.5
Issuance (Retirement) of Stock, Net -750 -750 -500 0
Issuance (Retirement) of Debt, Net -1002.2 -1002.2 0 0
Foreign Exchange Effects 20 -55.7 -122.9 -70.6 -9.4
Net Change in Cash -521.1 1157.9 1414.2 385.2 -512.1

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Biogen Company profile

Biogen Inc. (BIIB) is a biotechnology company in the field of neurological and neurodegenerative diseases. 

Established in 1978 and headquartered in Cambridge, Massachusetts, Biogen has devoted its scientific research to defeating neurological diseases, like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). 

With the aid of some of the world’s leading neuroscientists and neurologists, Biogen has sought treatments against common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP). 

The use of advanced technologies and engineering skills has enabled Biogen to bring effective medicines to the market. The company’s products include SPINRAZA for the treatment of SMA; TECFIDERA, AVONEX, FAMPYRA, VUMERITY and TYSABRI for multiple sclerosis; ADUHELM for Alzheimer’s disease; and FUMADERM for the treatment of severe plaque psoriasis.

Biogen has made an agreement with Genentech, a member of the Roche Group for business and financial rights, with respect to RITUXAN, GAZYVA and OCREVUS. It’s constantly looking at ways to improve its research and development to compete against other biotech giants like Pfizer Inc (PFE), Johnson & Johnson (JNJ) and Amgen (AMGN). 

Biogen went public in September 1991. It trades on the Nasqaq under the ticker ‘BIIB’.

Industry: Biopharmaceuticals

225 Binney Street
CAMBRIDGE
MASSACHUSETTS 02142
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.63 Price
+2.040% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

70,871.20 Price
+2.740% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading